Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 10.011
Filtrar
1.
Biomed Res Int ; 2021: 8871287, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33855086

RESUMEN

Background: Facility-based death review committee (DRC) of neonatal deaths and stillbirths can encourage stakeholders to enhance the quality of care during the antenatal period and labour to improve birth outcomes. To understand the benefits and impact of the DRCs, this study was aimed at exploring the DRC members' perception about the role and benefits of the newly developed facility-based DRCs in five pilot hospitals in Jordan, to assess women empowerment, decision-making process, power dynamics, culture and genderism as contributing factors for deaths, and impact of COVID-19 lockdown on births. Methods: A descriptive study of a qualitative design-using focus group discussions-was conducted after one year of establishing DRCs in 5 pilot large hospitals. The number of participants in each focus group ranged from 8 to10, and the total number of participants was 45 HCPs (nurses and doctors). Questions were consecutively asked in each focus group. The moderator asked the main questions from the guide and then used probing as needed. A second researcher observed the conversation and took field notes. Results: Overall, there was an agreement among the majority of DRC members across all hospitals that the DRC was successful in identifying the exact cause of neonatal deaths and stillbirths as well as associated modifiable factors. There was also a consensus that the DRC contributed to an improvement in health services provided for pregnant women and newborns as well as protecting human rights and enabling women to be more interdependent in taking decisions related to family planning. Moreover, the DRC agreed that a proportion of the neonatal deaths and stillbirths occurring in the hospitals could have been prevented if adequate antenatal care was provided and some traditional harmful practices were avoided. Conclusions: Facility-based neonatal death review audit is practical and can be used to identify exact causes of maternal and neonatal deaths and is a valuable tool for hospital quality indicators. It can also change the perception and practice of health care providers, which may be reflected in improving the quality of provided healthcare services.


Asunto(s)
Comités Consultivos , Actitud Frente a la Salud , Muerte Perinatal , Mortinato , Comités Consultivos/organización & administración , Toma de Decisiones , Femenino , Grupos Focales , Personal de Salud , Hospitales , Derechos Humanos , Humanos , Recién Nacido , Control de Infecciones/métodos , Unidades de Cuidado Intensivo Neonatal , Jordania , Muerte Perinatal/prevención & control , Embarazo , Mujeres Embarazadas , Atención Prenatal
4.
Saudi Med J ; 42(4): 355-362, 2021 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-33795490

RESUMEN

Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis and viral pneumonia in pediatrics worldwide. In the Kingdom of Saudi Arabia (KSA), the prevalence of RSV is 23.5% in pediatric patients with acute lower respiratory tract illness. Coronavirus disease (COVID-19) poses critical public health and socioeconomic challenges in KSA. The Saudi Pediatric Pulmonology Association (SPPA), a subsidiary of the Saudi Thoracic Society (STS), developed a task force to determine the potential challenges and barriers to the RSV immunoprophylaxis program during the era of COVID-19 and to compose a practical, nationwide, and multidisciplinary approach to address these challenges. Some of the recommendations to manage these challenges include increasing the number of RSV immunoprophylaxis clinics, drive-thru visits, home-care services, and swift referrals to the RSV immunoprophylaxis program specialists. Additional training is required for healthcare personnel to add RSV immunoprophylaxis to the regular immunization schedule.


Asunto(s)
Antivirales/uso terapéutico , Bronquiolitis Viral/prevención & control , Prestación de Atención de Salud/métodos , Programas de Inmunización/métodos , Palivizumab/uso terapéutico , Infecciones por Virus Sincitial Respiratorio/prevención & control , Comités Consultivos , /prevención & control , Servicios de Atención de Salud a Domicilio , Humanos , Lactante , Recién Nacido , Inyecciones , Neumología , Arabia Saudita , Sociedades Médicas
5.
MMWR Morb Mortal Wkly Rep ; 70(17): 651-656, 2021 Apr 30.
Artículo en Inglés | MEDLINE | ID: mdl-33914723

RESUMEN

On February 27, 2021, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the Janssen COVID-19 (Ad.26.COV2.S) vaccine (Janssen Biotech, Inc., a Janssen Pharmaceutical company, Johnson & Johnson; New Brunswick, New Jersey), and on February 28, 2021, the Advisory Committee on Immunization Practices (ACIP) issued interim recommendations for its use in persons aged ≥18 years (1,2). On April 13, 2021, CDC and FDA recommended a pause in the use of the Janssen COVID-19 vaccine after reports of six U.S. cases of cerebral venous sinus thrombosis (CVST) with thrombocytopenia, a rare thromboembolic syndrome, among Janssen COVID-19 vaccine recipients (3). Two emergency ACIP meetings were rapidly convened to review reported cases of thrombosis with thrombocytopenia syndrome (TTS) and to consider updated recommendations for use of the Janssen COVID-19 vaccine in the United States. On April 23, 2021, after a discussion of the benefits and risks of resuming vaccination, ACIP reaffirmed its interim recommendation for use of the Janssen COVID-19 vaccine in all persons aged ≥18 years under the FDA's EUA, which now includes a warning that rare clotting events might occur after vaccination, primarily among women aged 18-49 years. Patient and provider education about the risk for TTS with the Janssen COVID-19 vaccine, especially among women aged <50 years, as well as the availability of alternative COVID-19 vaccines, is required to guide vaccine decision-making and ensure early recognition and clinical management of TTS.


Asunto(s)
/administración & dosificación , Aprobación de Drogas , Guías de Práctica Clínica como Asunto , Trombocitopenia/epidemiología , Trombosis/epidemiología , Adolescente , Adulto , Sistemas de Registro de Reacción Adversa a Medicamentos , Comités Consultivos , /prevención & control , Centers for Disease Control and Prevention, U.S. , Etiquetado de Medicamentos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Medición de Riesgo , Retirada de Medicamento por Seguridad , Estados Unidos/epidemiología , United States Food and Drug Administration , Adulto Joven
7.
J Med Life ; 14(1): 93-99, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33767792

RESUMEN

Intellectual property rights such as Copyright, Trademark, Patents and Trade secrets etc. help us to gain some protection against certain inventions by acknowledging the founder. In today's industry it is agreed that Intellectual Property Rights has a big role to play. This current study envisages the knowledge, attitude, practice regarding Intellectual Property Rights among dental task force attending private dental colleges.The survey was conducted among students of which were Interns, Post Graduates, faculty members and other dental surgeons attending private dental colleges in Navi Mumbai. The subjects of this study comprised of a total of 1020 students, faculty members and other dental surgeons from five different private dental institutes. The survey includes closed ended questions. Data analysis was performed using SPSS software version 17. Explaining calculations were used to summarize all the answers. A total of 889 students, faculty and other dental surgeons from private dental colleges responded. Results showed that about 83.5% believe the statement "Articles and other publications are protected by copyright." 66.6% of participants would select trademark in order to protect their clinic or organization name. About 38.7% were aware of the term Intellectual Property Rights. It also suggests that only 10.9% have attended any seminar/conference pertaining to IPR. The students and faculty members have an overall sense of eagerness to learn and gain more knowledge based on IPR. Thus conducting more workshops and seminars based on IPR should be encouraged.


Asunto(s)
Comités Consultivos , Educación en Odontología , Conocimientos, Actitudes y Práctica en Salud , Propiedad Intelectual , Universidades , Estudios Transversales , Humanos
10.
J Fam Pract ; 70(2): 86;89;92, 2021 03.
Artículo en Inglés | MEDLINE | ID: mdl-33760898
12.
16.
MMWR Morb Mortal Wkly Rep ; 70(6): 189-192, 2021 Feb 12.
Artículo en Inglés | MEDLINE | ID: mdl-33571172

RESUMEN

At its October 2020 meeting, the Advisory Committee on Immunization Practices* (ACIP) approved the 2021 Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger. After Emergency Use Authorization of Pfizer-BioNTech COVID-19 vaccine by the Food and Drug Administration (FDA), ACIP issued an interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine in persons aged ≥16 years at its December 12, 2020, meeting (1). In addition, ACIP approved an amendment to include COVID-19 vaccine recommendations in the child and adolescent immunization schedule. After Emergency Use Authorization of Moderna COVID-19 vaccine by FDA, ACIP issued an interim recommendation for use of Moderna COVID-19 vaccine in persons aged ≥18 years at its December 19, 2020, emergency meeting (2).


Asunto(s)
Inmunización/normas , Guías de Práctica Clínica como Asunto , Vacunas/administración & dosificación , Adolescente , Comités Consultivos , Centers for Disease Control and Prevention, U.S. , Niño , Preescolar , Humanos , Esquemas de Inmunización , Lactante , Estados Unidos
17.
MMWR Morb Mortal Wkly Rep ; 70(6): 193-196, 2021 Feb 12.
Artículo en Inglés | MEDLINE | ID: mdl-33571173

RESUMEN

At its October 2020 meeting, the Advisory Committee on Immunization Practices (ACIP)* approved the Recommended Immunization Schedule for Adults Aged 19 Years or Older, United States, 2021. After the Emergency Use Authorization of Pfizer-BioNTech COVID-19 vaccine by the Food and Drug Administration, ACIP issued an interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine in persons aged ≥16 years at its December 12, 2020, emergency meeting (1). In addition, ACIP approved an amendment to include COVID-19 vaccine recommendations in the child and adolescent and adult immunization schedules. After Emergency Use Authorization of Moderna COVID-19 vaccine by the Food and Drug Administration, ACIP issued an interim recommendation for use of Moderna COVID-19 vaccine in persons aged ≥18 years at its December 19, 2020, emergency meeting (2).


Asunto(s)
Inmunización/normas , Guías de Práctica Clínica como Asunto , Vacunas/administración & dosificación , Adulto , Comités Consultivos , Centers for Disease Control and Prevention, U.S. , Humanos , Esquemas de Inmunización , Estados Unidos
19.
J Frailty Aging ; 10(2): 168-175, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33575707

RESUMEN

Interactions among physiological pathways associated with osteoporosis and sarcopenia are thought to contribute to the onset of frailty. The International Conference on Frailty and Sarcopenia Research Task Force thus met in March 2020 to explore how emerging interventions to manage fracture and osteoporosis in older adults may reduce frailty, disability, morbidity, and mortality in the older population. Both pharmacological and non-pharmacological interventions (including nutritional intervention, exercise, and other lifestyle changes) were discussed, including nutritional intervention, exercise, and other lifestyle changes. Pharmacological treatments for osteoporosis include bone-forming and antiresorptive agents, which may optimally be used in sequential or combination regimens. Since similar mechanisms related to resorption underlie physiological changes in muscle and bone, these interventions may provide benefits beyond treating osteoporosis. Clinical trials to test these interventions, however, often exclude frail older persons because of comorbidities (such as mobility disability and cognitive impairment) or polypharmacy. The Task Force recommended that future clinical trials use harmonized protocols, including harmonized inclusion criteria and similar outcome measures; and that they test a range of multidomain therapies. They further advocated more high-quality research to develop interventions specifically for people who are frail and old. The ICOPE program recommended by WHO appears to be highly recommended to frail older adults with osteoporosis.


Asunto(s)
Comités Consultivos , Investigación Biomédica , Anciano Frágil , Osteoporosis , Anciano , Anciano de 80 o más Años , Ensayos Clínicos como Asunto , Congresos como Asunto , Humanos , Osteoporosis/terapia
20.
Dermatol Surg ; 47(2): 227-234, 2021 02 01.
Artículo en Inglés | MEDLINE | ID: mdl-33565776

RESUMEN

BACKGROUND: As the use of injectable skin fillers increase in popularity, an increase in the reported adverse events is expected. OBJECTIVE: This systematic review supports the development of American Society for Dermatologic Surgery practice guideline on the management of adverse events of skin fillers. METHODS AND MATERIALS: Several databases for studies on risk factors or treatments of injection-related visual compromise (IRVC), skin necrosis, inflammatory events, and nodules were searched. Meta-analysis was conducted when feasible. RESULTS: The review included 182 studies. However, IRVC was very rare (1-2/1,000,000 patients) but had poor prognosis with improvement in 19% of cases. Skin necrosis was more common (approximately 5/1,000) with better prognosis (up to 77% of cases showing improvement). Treatments of IRVC and skin necrosis primarily depend on hyaluronidase injections. Risk of skin necrosis, inflammatory events, and nodules may be lower with certain fillers, brands, injection techniques, and volume. Treatment of inflammatory events and nodules with antibiotics, corticosteroids, 5-FU, and hyaluronidase was associated with high response rate (75%-80%). Most of the studies were small and noncomparative, making the evidence certainty very low. CONCLUSION: Practitioners must have adequate knowledge of anatomy, elicit history of skin filler use, and establish preemptive protocols that prepare the clinical practice to manage complications.


Asunto(s)
Técnicas Cosméticas/efectos adversos , Rellenos Dérmicos/efectos adversos , Reacción en el Punto de Inyección/terapia , Guías de Práctica Clínica como Asunto , Comités Consultivos/normas , Toma de Decisiones Clínicas , Rellenos Dérmicos/administración & dosificación , Dermatología/normas , Estética , Medicina Basada en la Evidencia/normas , Cara/anatomía & histología , Humanos , Reacción en el Punto de Inyección/etiología , Comunicación Interdisciplinaria , Necrosis/inducido químicamente , Necrosis/terapia , Piel/irrigación sanguínea , Piel/efectos de los fármacos , Piel/inervación , Piel/patología , Sociedades Médicas/normas , Especialidades Quirúrgicas/normas , Estados Unidos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...